search
Back to results

Cryoballoon Isolation of Superior Vena Cava in Paroxysmal Atrial Fibrillation (CISPAF)

Primary Purpose

Atrial Fibrillation

Status
Unknown status
Phase
Not Applicable
Locations
Croatia
Study Type
Interventional
Intervention
superior vena cava isolation
pulmonary vein isolation
Sponsored by
University of Zagreb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring pulmonary vein isolation, superior vena cava isolation, cryoballoon ablation

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • paroxysmal atrial fibrillation scheduled for cryoballoon the ablation of atrial fibrillation (indication not related to the study)

Exclusion Criteria:

persistent atrial fibrillation

  • renal failure
  • contrast allergy

Sites / Locations

  • KBC ZagrebRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

SVC arm

PVI arm

Arm Description

Patients who will receive SVC isolation by the means of cryoballoon after the PVI procedure

Patients who will receive convectional cryoballoon PVI procedure

Outcomes

Primary Outcome Measures

efficacy
percentage of patients free of any atrial arrhythmias during the one year of follow up (occurrence of any atrial arrhythmia longer than 30 seconds, detected by Holter EKG or 12 lead EKG will be considered as treatment failure)

Secondary Outcome Measures

feasibility
the success rates of SVC isolation. percentage of patients in whom successful SVC isolation was performed. SVC isolation will be verified by the circular mapping catheter, after the application of cryoballoon lesion. The absence of electrical signals in SVC after the ablation is considered as a successful isolation.
safety
adverse events during the procedure (specials consideration on phrenic nerve palsy) and after the procedure (groin hematoma, pericardial effusion, etc)

Full Information

First Posted
June 7, 2021
Last Updated
October 4, 2021
Sponsor
University of Zagreb
search

1. Study Identification

Unique Protocol Identification Number
NCT05081310
Brief Title
Cryoballoon Isolation of Superior Vena Cava in Paroxysmal Atrial Fibrillation
Acronym
CISPAF
Official Title
Cryoballoon Isolation of Superior Vena Cava in Paroxysmal Atrial Fibrillation - a Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
July 30, 2022 (Anticipated)
Study Completion Date
July 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Zagreb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There is still unresolved question whether isolation of superior vena cava (SVC) in conjunction to conventional pulmonary vein isolation (PVI) improves outcomes in the treatment of paroxysmal atrial fibrillation. The investigators are conducting a randomized study to determine if SVC isolation (in addition to pulmonary vein isolation) with the cryoballoon technology can improve freedom from atrial arrhythmias in one year follow up after the ablation.
Detailed Description
Paroxysmal atrial fibrillation can be triggered by non-pulmonary vein foci, like the superior vena cava. There are some older publications showing improved result in terms of freedom from atrial tachycardias when electrical isolation of this vessel utilizing radiofrequency energy is achieved. Recent retrospective studies showed that isolation of superior vena cava by the means of cryoballoon technology is safe and feasible procedure. Furthermore, one retrospective cohort study showed improved outcomes of SVC insolation + PVI versus PVI only strategy. To our knowledge there is still no randomized data that compared SVC isolation + PVI vs PVI only strategy when using cryoballoon technology. The investigators want to determine if SVC isolation by the means of cryoballoon technology in conjunction with PVI can improve the patients outcomes. Also, there will be focus on the safety of the procedure, especially regarding the right sided phrenic nerve palsy. The primary objective of the study is freedom from atrial arrhythmias defined by standard postprocedural monitoring by ECG and Holter monitors. The investigators are conducting a randomized study with 1:1 randomization and planning to enroll around 100 participants with 1 year follow up. One group will receive conventional cryoballoon pulmonary vein isolation, and other group will receive SVC isolation after the PVI procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
pulmonary vein isolation, superior vena cava isolation, cryoballoon ablation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SVC arm
Arm Type
Experimental
Arm Description
Patients who will receive SVC isolation by the means of cryoballoon after the PVI procedure
Arm Title
PVI arm
Arm Type
Active Comparator
Arm Description
Patients who will receive convectional cryoballoon PVI procedure
Intervention Type
Device
Intervention Name(s)
superior vena cava isolation
Intervention Description
SVC isolation by the means of cryoballoon
Intervention Type
Device
Intervention Name(s)
pulmonary vein isolation
Intervention Description
conventional pulmonary vein isolation by the means of cryoballoon
Primary Outcome Measure Information:
Title
efficacy
Description
percentage of patients free of any atrial arrhythmias during the one year of follow up (occurrence of any atrial arrhythmia longer than 30 seconds, detected by Holter EKG or 12 lead EKG will be considered as treatment failure)
Time Frame
one year
Secondary Outcome Measure Information:
Title
feasibility
Description
the success rates of SVC isolation. percentage of patients in whom successful SVC isolation was performed. SVC isolation will be verified by the circular mapping catheter, after the application of cryoballoon lesion. The absence of electrical signals in SVC after the ablation is considered as a successful isolation.
Time Frame
during the procedure
Title
safety
Description
adverse events during the procedure (specials consideration on phrenic nerve palsy) and after the procedure (groin hematoma, pericardial effusion, etc)
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: paroxysmal atrial fibrillation scheduled for cryoballoon the ablation of atrial fibrillation (indication not related to the study) Exclusion Criteria: persistent atrial fibrillation renal failure contrast allergy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vedran Velagic, MD, PhD
Phone
0917929284
Email
vvelagic@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Vedran Pasara, MD
Phone
0917302512
Email
vedran.pasara@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vedran Velagic, MD, PhD
Organizational Affiliation
Clinical Hospital Centre Zagreb
Official's Role
Principal Investigator
Facility Information:
Facility Name
KBC Zagreb
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vedran Velagić, MD, PhD
Phone
0917929284
Email
vvelagic@gmail.com
First Name & Middle Initial & Last Name & Degree
Ivan Prepolec, MD
First Name & Middle Initial & Last Name & Degree
Vedran Pasara, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33447964
Citation
Overeinder I, Osorio TG, Calburean PA, Bisignani A, Bala G, Sieira J, Stroker E, Al Houssari M, Mojica J, Boveda S, Paparella G, Brugada P, de Asmundis C, Chierchia GB. Comparison between superior vena cava ablation in addition to pulmonary vein isolation and standard pulmonary vein isolation in patients with paroxysmal atrial fibrillation with the cryoballoon technique. J Interv Card Electrophysiol. 2021 Dec;62(3):579-586. doi: 10.1007/s10840-020-00932-6. Epub 2021 Jan 15.
Results Reference
background
PubMed Identifier
32250512
Citation
Wei HQ, Guo XG, Sun Q, Yang JD, Xie HY, Cao ZJ, Chen YQ, Zhang S, Wu S, Ma J. Electrical isolation of the superior vena cava using second-generation cryoballoon in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2020 Jun;31(6):1307-1314. doi: 10.1111/jce.14477. Epub 2020 Apr 11.
Results Reference
background
PubMed Identifier
32253600
Citation
Iacopino S, Osorio TG, Filannino P, Artale P, Sieira J, Stroker E, Bala G, Overeinder I, Hacioglu E, Calburean PA, Paparella G, Brugada P, de Asmundis C, Chierchia GB. Safety and feasibility of electrical isolation of the superior vena cava in addition to pulmonary vein ablation for paroxysmal atrial fibrillation using the cryoballoon: lessons from a prospective study. J Interv Card Electrophysiol. 2021 Mar;60(2):255-260. doi: 10.1007/s10840-020-00740-y. Epub 2020 Apr 6.
Results Reference
background

Learn more about this trial

Cryoballoon Isolation of Superior Vena Cava in Paroxysmal Atrial Fibrillation

We'll reach out to this number within 24 hrs